Annovis Bio's CEO Discusses the promise of Buntanetap in Redefining the Treatment of Alzheimer's and Parkinson's and Next Steps Artwork

WTR Biotech Spotlight

WTR Biotech Spotlight is a biweekly conversation with biotech executives, medical experts, and investors on recent clinical data or industry-driving events in biotech.

All Episodes

WTR Biotech Spotlight

Annovis Bio's CEO Discusses the promise of Buntanetap in Redefining the Treatment of Alzheimer's and Parkinson's and Next Steps

March 19, 2025 • Joe Brunetto • Season 1 • Episode 4

Founding CEO and President of Annovis Bio (NYSE: ANVS) Dr Maria Maccecchini joins WTR's Tim Gerdeman and Robert Sassoon in this week's WTR Biotech Spotlight episode. Annovis is a late clinical-stage drug platform company developing novel disease-modifying therapies for neurodegenerative diseases, to include targeting Alzheimer's and Parkinson's, as well as other related diseases. Dr Maccecchini discusses the company's lead drug candidate Buntanetap and its promise as a treatment that can go beyond simply slowing the rate of cognitive decline in Alzheimer's and Parkinson's patients.